Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.35 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9289504 | 0.95 | CYP11B2 (0.43) | CYP11B2DYRK1AKMT2ANAMPTKDM4E | |
| SCHEMBL768748 | 0.85 | CYP11B2 (0.46) | CYP11B2KMT2AKDM4ESMN1; SMN2MAPT | |
| SCHEMBL30417046 | 0.85 | CYP11B2 (0.46) | CYP11B2KMT2AKDM4ESMN1; SMN2MAPT | |
| SCHEMBL748924 | 0.82 | SMN1; SMN2 (0.37) | KMT2AKDM4ESMN1; SMN2MAPTHTT | |
| SCHEMBL13188717 | 0.81 | NAMPT (0.44) | CYP11B2DYRK1AKMT2ANAMPTSMN1; SMN2 | |
| SCHEMBL768816 | 0.79 | CA2 (0.45) | KMT2AKDM4ESMN1; SMN2HTTCYP19A1 | |
| SCHEMBL31226386 | 0.78 | CA2 (0.36) | KDM4ESMN1; SMN2MAPTHTT | |
| SCHEMBL1607471 | 0.77 | SMN1; SMN2 (0.35) | CYP11B2KMT2AKDM4ESMN1; SMN2MAPT | |
| SCHEMBL28089087 | 0.77 | KDM4E (0.42) | KDM4ESMN1; SMN2MAPTHTTRAB9A | |
| SCHEMBL21193741 | 0.77 | DYRK1A (0.55) | CYP11B2DYRK1AKMT2ASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109843879-B | Benzothiazole derivatives as DYRK1 inhibitors | 药物治疗股份有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-115916966-A | STRAD binding agents and uses thereof | 加利福尼亚大学董事会 | 2023-04-04 | — | — | CN | disclosed |
| WO-2021155004-A1 | STRAD-BINDING AGENTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2018069468-A1 | BENZOTHIAZOLE DERIVATIVES AS DYRK1 INHIBITORS | PHARMASUM THERAPEUTICS AS (NO) | 2018-04-19 | — | — | WO | disclosed |
| EP-2307371-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2017-10-04 | — | — | EP | disclosed |
| EP-2307371-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2017-10-04 | — | — | EP | disclosed |
| US-9242963-B2 | Organic compounds | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-9242963-B2 | Organic compounds | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-20150210672-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| US-20150210672-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| US-8791141-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-07-29 | — | — | US | disclosed |
| US-8791141-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-07-29 | — | — | US | disclosed |
| US-8030334-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-10-04 | — | — | US | disclosed |
| US-8030334-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-10-04 | — | — | US | disclosed |
| US-8030334-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-10-04 | — | — | US | disclosed |
| US-20110082129-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-04-07 | — | — | US | disclosed |
| US-20110082129-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-04-07 | — | — | US | disclosed |
| US-20100261698-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| US-20100261698-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| US-20100261698-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082129-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | CYP11B2 13/4885DYRK1A 4856/4885KMT2A 4447/4885 |
| US-20100261698-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | CYP11B2 13/4885DYRK1A 4856/4885KMT2A 4447/4885 |
| US-20150210672-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | CYP11B2 12/4885DYRK1A 4802/4885KMT2A 4274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.